Remarkably, we found a certain proportion of RDAA-positive cases from NSCLC patients with EGFR mutation (Supplementary Fig. 8, up row) suggesting that RDAA could coexist with other mutation-driven tumorigenic factors. This evidence concerns the gene EGFR and non-small cell lung carcinoma.